Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)
09 Febrero 2021 - 4:22PM
Edgar (US Regulatory)
Free
Writing Prospectus dated February 9, 2021
Filed
pursuant to Rule 433
Relating
to the Preliminary Prospectus Supplement dated
February
9, 2021
Registration
Statement No. 333-232009
Enlivex
Announces $10 Million Bought Deal Offering of Ordinary Shares
Nes
Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming
immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that
it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase
on a firm commitment basis 500,000 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00
per ordinary share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about
February 12, 2021, subject to satisfaction of customary closing conditions.
H.C.
Wainwright & Co. is acting as the sole book-running manager for the offering.
The
Company also has granted to the underwriter a 30-day option to purchase up to 75,000 additional ordinary shares at the public
offering price, less underwriting discounts and commissions.
The
gross proceeds to Enlivex, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise
of the underwriter’s option to purchase additional ordinary shares, are expected to be $10 million. The Company
intends to use the net proceeds from this offering for (i) clinical, regulatory, manufacturing and research and development activities;
(ii) potential acquisitions and in-licensing; and (iii) other general corporate purposes.
The
securities described above are being offered by Enlivex pursuant to a “shelf” registration statement on Form F-3 (File
No. 333-232009) previously filed with the Securities and Exchange Commission (the “SEC”) on June 7, 2019 and declared
effective by the SEC on June 21, 2019. The offering of the securities is being made only by means of a prospectus, including a
prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying
prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the preliminary prospectus
supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or
by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or
e-mail at placements@hcwco.com.
This
press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be
any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such state or other jurisdiction.
About
Enlivex
Enlivex
is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf
cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their
homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information,
visit http://www.enlivex.com.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such
as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,”
“believes,” “should,” “would”, “could,” “intends,” “estimates,”
“suggests,” “has the potential to” and other words of similar meaning, including statements regarding
expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness
of, market opportunities for, ALLOCETRATM programs, and statements relating to the bought deal offering, including
as to the consummation of the offering described above, the expected proceeds from the offering, the intended use of proceeds
and the timing of the closing of the offering. All such forward-looking statements are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve
risks and uncertainties that may affect Enlivex’s business and prospects, including market and other conditions and the
risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development
may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or
marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue
to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those
set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly
from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the
results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line
could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional
time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive
products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.
In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological
and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s
most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements
contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to
update forward-looking statements, except as required under applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com
INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com
Enlivex Therapeutics (NASDAQ:ENLV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024